ShajiKKumarMD

Hematology • Rochester, MN

Hematologic Oncology

Consultant at Mayo Clinic

Join to view full profile

Dr. Kumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kumar's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2003
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1997 - 1999
Institute Rotary Cancer Hospital, All-India Institute of Medical SciencesSenior Resident, 1996 - 1997
All India Institute of Medical SciencesClass of 1993
All-India Institute of Medical SciencesInternship, Rotatory, 1992
All-India Institute of Medical SciencesMB BS, 1987 - 1991
Union Christian CollegePre-Medical, 1985 - 1987

Certifications & Licensure

MN State Medical License 1999 - 2024
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Merit Award American Society of Clinical Oncology, 2003
William Summerskill Award Department of Internal Medicine, Mayo, 2003
Travel Award for Presentation at Special Topic Conference on Hepatic Veno-occlusive Disease, Atlanta, GA American Association for the Study of Liver Diseases, 2002
Methods in Clinical Cancer Research Award American Association for Cancer Research amd American Society of Clinical Oncology Workshop, 2002
Cancer Education Consortium Award Epidemiology and Trial Design, Brewster, MA, 2002
American Association of Cancer Research Award Molecular Biology Workshop, Aspen, CO, 2001
Kirpal Kaur Award for Best Resident Department of Medicine, All India Institute of Medical Sciences, New Delhi, 1993
Join now to see all

Clinical Trials

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer Start of enrollment: 2005 Dec 01
Completed
Phase 1
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Start of enrollment: 2007 Aug 29
Completed
Phase 1, Phase 2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2006 Jul 01
Completed
Phase 2
Sunitinib in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2007 Sep 01
Completed
Phase 2
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2007 Dec 01
Completed
Phase 2
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2008 May 01
Terminated
Phase 2
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Aug 01
Terminated
Phase 1
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Dec 03
Completed
Phase 2
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant Start of enrollment: 2009 Dec 01
Completed
Phase 2
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis Start of enrollment: 2010 Mar 01
Completed
Phase 2
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Start of enrollment: 2012 Jan 31
Active, not recruiting
Phase 2
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2012 Dec 19
Completed
Phase 1
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide Start of enrollment: 2014 Mar 01
Completed
Phase 2
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant Start of enrollment: 2013 Aug 01
Withdrawn
Phase 2
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis Start of enrollment: 2013 Aug 20
Active, not recruiting
Phase 1, Phase 2
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2013 Aug 01
Completed
Phase 1
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2014 Jun 30
Completed
Phase 1, Phase 2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant Start of enrollment: 2018 May 25
Active, not recruiting
Phase 2
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2018 May 02
Completed
Phase 1
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2020 Aug 07
Withdrawn
Phase 2
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) Start of enrollment: 2019 Sep 25
Active, not recruiting
Phase 1, Phase 2
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Start of enrollment: 2022 Feb 16
Active, not recruiting
Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial Start of enrollment: 2021 Feb 24
Recruiting
Phase 3
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Start of enrollment: 2021 Jun 03
Completed
Phase 1, Phase 2
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2020 Feb 05
Terminated
Phase 1
Roles: Principal Investigator
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Start of enrollment: 2024 Feb 15
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Active, not recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy ...> ;BMC Cancer. 2024 Apr 29
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.
Darshi Shah, Charalampos Charalampous, Shaji Kumar, Rajshekhar Chakraborty> ;Annals of Hematology. 2024 Apr 17
High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.
Matthew J Rees, Shaji Kumar> ;American Journal of Hematology. 2024 Apr 13
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Josell...> ;Leukemia. 2024 Apr 9
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalv...> ;Blood Cancer Journal. 2024 Mar 26
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.
Eric M Ammann, Alex Z Fu, Shuchita Kaila, Annette Lam, Thierry Facon, Brian G M Durie, Shaji K Kumar, Saad Z Usmani> ;Advances in Therapy. 2024 May 1
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.
John Devin Peipert, Fengmin Zhao, Ju-Whei Lee, Shu-En Shen, Edward Ip, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Pamela J Raper,...> ;JAMA Network Open. 2024 Mar 4
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Irene M Ghobrial, Nicole Gormley, Shaji K Kumar, Maria-Victoria Mateos, P Leif Bergsagel, Marta Chesi, Madhav V Dhodapkar, Angela Dispenzieri, Rafael Fonseca, Gad Getz...> ;Blood Cancer Discovery. 2024 May 1
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees, M., Kumar, S.> ;Leukemia & Lymphoma. 2024 Mar 1
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide an...
Karthik Ramasamy, Nizar J Bahlis, Shaji K Kumar, Arun Kumar, Holly Cranmer, Bingxia Wang, Jonathan Dabora, Richard Labotka, Paul G Richardson, Philippe Moreau> ;Haematologica. 2024 Feb 29
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.
Nadine Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, P Leif Bergsagel, S Vincent Rajkumar> ;Leukemia. 2024 Feb 28
Don't let the genie out of the bottle!
Shaji Kumar> ;Blood. 2024 Feb 15
1 citations
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine EC...
Walter, A., Lee, J., Streck, J., Gareen, I., Herman, B., Kircher, S., Carlos, R., Kumar, S., Mayer, I., Saba, N., Fenske, T., Neal, J., Atkins, M., Hodi, F., Kyriakopo...> ;Cancer. 2024 Feb 1
1 citations
Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah, N., Lakshman, A., Kumar, S., Cook, J., Binder, M., Kapoor, P., Dispenzieri, A., Gertz, M., Lacy, M., Hayman, S., Buadi, F., Dingli, D., Lin, Y., Kourelis, T....> ;Blood Cancer Journal. 2024 Jan 17
New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma.
Abdallah, N., Kumar, S.> ;Hematology/oncology Clinics of North America. 2024 Apr 1
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel P Burbano, Patrick J O'Brien, Francis K Buadi, Suzanne Hayman, Shaji K Kumar, Wilson I Gonsalves> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 May 1
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2024 Jan 1
Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
Bergsagel, P., Rajkumar, S., Kumar, S.> ;Hematology/oncology Clinics of North America. 2024 Apr 1
Muscle and fat composition in patients with newly diagnosed multiple myeloma.
Abdallah, N., Nagayama, H., Takahashi, N., Gonsalves, W., Fonder, A., Dispenzieri, A., Dingli, D., Buadi, F., Lacy, M., Hobbs, M., Gertz, M., Binder, M., Kapoor, P., W...> ;Blood Cancer Journal. 2023 Dec 12
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous, C., Goel, U., Kapoor, P., Binder, M., Buadi, F., Cook, J., Dingli, D., Dispenzieri, A., Fonder, A., Gertz, M., Gonsalves, W., Hayman, S., Hobbs, M., Hwa,...> ;Blood Cancer Journal. 2023 Dec 11
1 citations
Sample average treatment effect on the treated (SATT) analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors as...
Amit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Raymond Shao, Feifan Liu, Qianqian Song, Jing Su, Shaji Kumar, Benjamin ...> ;Blood Cancer Journal. 2023 Dec 7
4 citations
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christoph...> ;Journal of the National Comprehensive Cancer Network. 2023 Dec 1
Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice.
Ritu Gupta, Dragan Jevremovic, Smith J Mathew, Shaji Kumar> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Din...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
1 citations
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.
Susan Bal, Noel Estrada-Merly, Luciano J Costa, Muzaffar H Qazilbash, Shaji Kumar, Anita D'Souza> ;Blood Cancer Journal. 2023 Nov 15
Join now to see all

Journal Articles

Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma
S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation
Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse
Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis
Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio
Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
Risk of MGUS in Relatives of Multiple Myeloma Cases by Clinical and Tumor Characteristics
Robert A Kyle, S Vincent Rajkumar, Alexandra J Greenberg, Abdul Rishi, Shaji Kumar, Nature
Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments.
Kumar S, Rajkumar SV, Greipp PR, Witzig TE, Am J Hematol
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A, Eur J Haematol
Reply to 'Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients'
Kumar S, Gertz MA, Leukemia
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma.
Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA, Bone Marrow Transplant
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.
Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan JR, Melton LJ, Rajkumar SV, Blood
Dexamethasone and the risk for adrenal suppression in multiple myeloma.
Ng AC, Kumar SK, Russell SJ, Rajkumar SV, Drake MT, Leukemia
Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM, Albright RC, Kamath PS, Litzow MR, Bone Marrow Transplant
CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.
Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE, Leukemia
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC, Blood
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S, Am J Hematol
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Sadek I, Dispenzieri A, Gertz MA, Kumar S, Leuk Lymphoma
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K, Dispenzieri A, Gertz M, Dingli D, Rajkumar SV, Kumar SK, Leukemia
Mesenteric venous thrombosis.
Kumar S, Sarr MG, Kamath PS, N Engl J Med
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, Gertz MA, Greipp PR, Witzig TE, Journal of Clinical Oncology
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation.
Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, Kumar S, Litzow MR, Schroeter AL, Arch Dermatol
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience.
Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, Kumar S, Greipp PR, Mayo Clin Proc
Join now to see all

Books/Book Chapters

Clinical malignant hematology.
Chapter: Monoclonal gammopathy of undetermined significance
Page 943 - 954Kumar S, Greipp PREditors: Sekeres MA, Kalaycio ME, Bolwell BJ.McGraw-Hill Medical, New York
Myeloma therapy: pursuing the plasma cell.
Chapter: Lenalidomide for initial therapy of newly diagnosed multiple myeloma
Page 279 - 288Kumar SEditors: Lonial S.Humana, Totowa
Antiangiogenic cancer therapy.
Chapter: Pathophysiologic role of VEGF in hematologic malignancies
Page 91 - 129Podar K, Kumar S, Chauhan D, Anderson KCEditors: Davis DW, Herbst RS, Abbruzzese JL.CRC Press, Boca Raton
Protein misfolding diseases: current and emerging principles and therapies.
Chapter: Current therapies for light-chain amyloidosis
Dispenzieri A, Kumar SEditors: Ramirez-Alvarado M; Kelly JW; Dobson CM.Wiley, Hoboken
Multiple Myeloma Kumar S. Vol. 1.
Kumar SDemos Medical, New York
Join now to see all

Abstracts/Posters

Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Germline Variation Predicts Treatment Response in Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Tra...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple My...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible f...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effectiveness of Daratumumab in Combination with Lenalidomide and Dexamethasone (DRd) Vs. Common Standard-of-Care Regimens in Patients with Non-Transplant Newly Diagno...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
Shaji K. Kumar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Approaches To Achieve the Best Possible Outcomes in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
2019 ASCO Annual Meeting - 6/1/2019
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Survivorship with Active Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
New Strategies for Multiple Myeloma Care: Next Steps for The Future
60th American Society of Hematology Annual Meeting - 11/30/2018
Advances in the management of multiple myeloma.
Hackensack University Medical Center Hackensack, New Jersey
Emerging Targets and Therapies in Myeloma.
9th Annual LLS Multiple Myeloma Conference Milwaukee
Stem Cell Transplantation for Myeloma: 2011 and Beyond.
Hematologic Malignancies: New Therapies and the Evolving Role of Transplant Chicago
Treatment of Newly Diagnosed Myeloma: Mayo Clinic Approach.
University Hospital Department of Hematology Krakow, Poland
When and why do I use maintenance therapy in myeloma?
Indian Society of Hematology Chandigarh, India
How I treat relapsed and / or refractory Multiple Myeloma?
Indian Society of Hematology Chandigarh, India
Management of Multiple Myeloma: Impact of Novel Molecules.
Targeted Therapy in Malignancy: Where the Future Is New Delhi
Emerging Treatment Options for Patients With Multiple Myeloma.
Fifth Annual Review of the ASH Annual Meeting: Updates in the Treatment and Management of ....
A Clinical Profile of Chronic Lymphocytic Leukemia.
Annual Conference of the Association of Physicians of India
Cyclosporine Therapy in Aplastic Anemia.
Annual Conference of Association of Physicians of India
Acquired von Willebrand’s Disease: A Single Institution Experience.
International Hemophilia Congress Montreal, Quebec, Canada
Join now to see all

Press Mentions

Triplet and Quadruplet Regimens in Smoldering Multiple MyelomaFebruary 22nd, 2023
Additional Advances in Multiple Myeloma Research and Clinical Trials with Shaji Kumar, MDJanuary 3rd, 2023
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual MeetingDecember 8th, 2022
Join now to see all